Skip to main content
SpringerLink
Log in

Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

High on-treatment platelet reactivity (HTPR) on clopidogrel correlates with adverse outcomes in patients treated with percutaneous coronary intervention (PCI). Whether HTPR is a modifiable risk factor for future events is not clear. We evaluated the effect of serial clopidogrel dose adjustment based on platelet function testing (PFT) during 12 months of dual antiplatelet therapy (DAPT) using Multiplate® analyzer in patients with HTPR after PCI in acute coronary syndrome on clinical outcome. Eighty-seven patients were randomized to interventional (n = 43) and control group (n = 44). Blood samples for PFT were drawn at day 1, 2, 3, 7, 30 and at month 2, 3, 6, 9 and 12. Clopidogrel dose was modified at each point of PFT in the interventional group with patients taking up to two additional 600 mg loading doses and a range of 75–300 mg maintenance dose to achieve and maintain optimal platelet reactivity (19–46 U). The incidence of the primary endpoint (composite of cardiovascular death, non-fatal myocardial infarction, target vessel revascularization and ischemic stroke) was significantly higher in the control group (36.3 vs 16.2 %; p = 0.034). There were no differences in total bleeding events (6.8 vs 4.6 %, p = ns). Patients in the interventional group maintained better P2Y12 inhibition during follow-up. We hypothesize that targeting the therapeutic window of platelet reactivity continuously throughout DAPT by dose adjustment of P2Y12 inhibitor may lead to better platelet reactivity control, and thus reduce the rate of ischemic complications in this high risk group of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European society of cardiology (ESC). Eur Heart J 32:2999–3054

    Article  PubMed  Google Scholar 

  2. Steg PG, James SK, Atar D et al (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33:2569–2619

    Article  PubMed  CAS  Google Scholar 

  3. O’Gara PT, Kushner FG, Ascheim DD et al (2013) 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 127:e362–e425

    Article  PubMed  Google Scholar 

  4. Jneid H, Anderson JL, Wright RS et al (2012) 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infaction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 126:875–910

    Article  PubMed  Google Scholar 

  5. Yusuf S, Zhao F, Mehta SR et al (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502

    Article  PubMed  CAS  Google Scholar 

  6. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:246–251

    Article  PubMed  CAS  Google Scholar 

  7. Wiviott SD, Braunwald E, McCabe CH et al (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Eng J Med 357:2001–2015

    Article  CAS  Google Scholar 

  8. Top 20 global products 2012 (2013) IMS Health Midas. http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-Line%20Market%20Data%20&%20Trends/Top_20_Global_Products_2012_2.pdf. Accessed 19 October 2013

  9. Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045–1057

    Article  PubMed  CAS  Google Scholar 

  10. Stone GW, Witzenbichler B, Weisz G et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382:614–623

    Article  PubMed  Google Scholar 

  11. Aradi D, Storey RF, Komócsi A et al (2014) Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 35:209–215

    Article  PubMed  PubMed Central  Google Scholar 

  12. Tantry US, Bonello L, Aradi D et al (2013) Consensus and update on the definition of on-treatment platelet reactivity to ADP associated with ischemia and bleeding. J Am Coll Cardiol 62:2261–2273

    Article  PubMed  CAS  Google Scholar 

  13. Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the BleedingAcademic Research Consortium. Circulation 123:2736–2747

    Article  PubMed  Google Scholar 

  14. Sibbing D, Braun S, Morath T et al (2009) Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 53:849–856

    Article  PubMed  CAS  Google Scholar 

  15. Sibbing D, Schulz S, Braun S et al (2010) Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement. J Thromb Haemost 8:250–256

    Article  PubMed  CAS  Google Scholar 

  16. Yusuf S, Mehta SR, Zhao F et al (2003) Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107:966–972

    Article  PubMed  CAS  Google Scholar 

  17. Hazarbasanov D, Velchev V, Finkov B et al (2012) Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. J Thromb Thrombolysis 34:85–90

    Article  PubMed  CAS  Google Scholar 

  18. Giles H, Smith REA, Martin J (1994) Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. Eur J Clin Invest 24:69–72

    Article  PubMed  CAS  Google Scholar 

  19. Gawaz M, Neumann FJ, Ott I et al (1996) Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 93:229–237

    Article  PubMed  CAS  Google Scholar 

  20. Muller I, Seyfarth M, Rudiger S et al (2001) Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 85:92–93

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Breet NJ, van Werkum JW, Bouman HJ et al (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303:754–762

    Article  PubMed  CAS  Google Scholar 

  22. Trenk D, Hochholzer W, Fromm MF et al (2008) Cytochrome P450 2C19 681G > A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 51:1925–1934

    Article  PubMed  CAS  Google Scholar 

  23. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS (2009) Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 103:1339–1343

    Article  PubMed  CAS  Google Scholar 

  24. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49:1505–1516

    Article  PubMed  CAS  Google Scholar 

  25. Lev EI, Patel RT, Maresh KJ et al (2006) Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47:27–33

    Article  PubMed  CAS  Google Scholar 

  26. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2005) Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54:2430–2435

    Article  PubMed  CAS  Google Scholar 

  27. Cuisset T, Frere C, Quilici J et al (2009) Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res 123:597–603

    Article  PubMed  CAS  Google Scholar 

  28. Kuchulakanti PK, Chu WW, Torguson R et al (2006) Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113:1108–1113

    Article  PubMed  CAS  Google Scholar 

  29. Price MJ, Berger PB, Teirstein PS et al (2011) Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105

    Article  PubMed  CAS  Google Scholar 

  30. Collet JP, Cuisset T, Rangé G et al (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367:2100–2109

    Article  PubMed  CAS  Google Scholar 

  31. Campo G, Parrinello G, Ferraresi P et al (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57:2474–2483

    Article  PubMed  CAS  Google Scholar 

  32. Parodi G, Marcucci R, Valenti R et al (2011) High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306:1215–1223

    Article  PubMed  CAS  Google Scholar 

  33. Brar SS, ten Berg J, Marcucci M et al (2011) Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: a collaborative meta-analysis of individual participant data. J Am Coll Cardiol 58:1945–1954

    Article  PubMed  Google Scholar 

  34. Aradi D, Pinter T, Magyari B et al (2014) Optimizing P2Y12-receptor inhibition in acute coronary syndrome after PCI using platelet function testing: impact of prasugrel versus high-dose clopidogrel. J Am Coll Cardiol 63:1061–1070

    Article  PubMed  CAS  Google Scholar 

  35. Arméro S, Camoin Jau L, Omar Aït Mokhtar O et al (2010) Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapy. Platelets 21:503–507

    Article  PubMed  Google Scholar 

  36. Gurbel PA, Bliden KP, Hayes KM et al (2005) The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 45:1392–1396

    Article  PubMed  CAS  Google Scholar 

  37. Mayer K, Schulz S, Bernlochner I et al. (2014) A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thromb Haemost 10;112(2)

  38. Siller-Matula JM, Francesconi M, Dechant C et al (2013) Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 167:2018–2023

    Article  PubMed  Google Scholar 

  39. Gurbel PA, Erlinge D, Ohman EM et al (2012) Platelet function during extended prasugrel and Clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA 308:1785–1794

    Article  PubMed  CAS  Google Scholar 

  40. Bonello L, Camoin-Jau L, Armero S et al (2009) Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 103:5–10

    Article  PubMed  CAS  Google Scholar 

  41. Chirumamilla AP, Maehara A, Mintz GS et al (2012) High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study. JACC Cardiovasc Imaging 5:540–549

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This investigation was funded by the Croatian Ministry of Science, Education and Sports.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Cardiovascular Diseases, University Hospital Center Zagreb, University of Zagreb School of Medicine, Kispaticeva 12, 10000, Zagreb, Croatia

    Jure Samardzic, Miroslav Krpan, Bosko Skoric, Marijan Pasalic & Davor Milicic

  2. Department of Cardiac Surgery, University Hospital Center Zagreb, University of Zagreb School of Medicine, Kispaticeva 12, 10000, Zagreb, Croatia

    Mate Petricevic

Authors
  1. Jure Samardzic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miroslav Krpan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bosko Skoric
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marijan Pasalic
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mate Petricevic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Davor Milicic
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jure Samardzic.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Samardzic, J., Krpan, M., Skoric, B. et al. Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity. J Thromb Thrombolysis 38, 459–469 (2014). https://doi.org/10.1007/s11239-014-1087-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-014-1087-0

Keywords

Search

Navigation